RedCare Pharmacy Outlook Raised, EBITDA +12%

RedCare Pharmacy Outlook Raised, EBITDA +12%

RedCare Pharmacy released a positive trading update ahead of its second‑quarter results scheduled for 29 July 2026. The update, cited by Jefferies, led the broker to raise the company’s fiscal‑2026 guidance across several key metrics.

Group revenue growth accelerated to 20 % year‑over‑year in April and May, up from 18 % in the first quarter. German prescription revenue grew 57 % year‑over‑year during the first two months of the second quarter, reaching €118 million.

Based on the stronger performance, RedCare lifted its fiscal‑2026 German prescription revenue target to a range of €680‑720 million, compared with the prior guidance of “above €670 million”. This implies an expected year‑over‑year increase of 35‑43 %.

German non‑prescription sales also improved, with year‑over‑year growth accelerating to 14 % – rising from 12 % in April to 16 % in May. International sales continued to expand at a steady 16 % year‑over‑year across nearly all markets.

The revised fiscal‑2026 outlook now projects overall group revenue growth of 15‑17 % (previously 13‑15 %) and non‑prescription sales growth of 10‑12 % (previously 8‑10 %). Adjusted EBITDA margin guidance was increased to a range of 2.5‑3.0 % from “above 2.5 %” earlier.

At the midpoint of the new margin range, the implied adjusted EBITDA amounts to €94 million, which is 12 % higher than the consensus estimate and above the prior guidance. Jefferies noted that an increased “fixum” from July onward should support achievement of this target.

RedCare confirmed that it will not publish the usual preliminary sales numbers in early July.